Category: 924909-16-0

On September 13, 2007, Blake, James F.; Boyd, Steven Armen; Cohen, Frederick; De Meese, Jason; Fong, Kin Chiu; Gaudino, John J.; Kaplan, Tomas; Marlow, Allison L.; Seo, Jeongbeob; Thomas, Allen A.; Tian, Hongqi; Young, Wendy B. published a patent.Related Products of 924909-16-0 The title of the patent was Heterobicyclic pyrazole compounds as Met tyrosine kinase inhibitors and their preparation and use. And the patent contained the following:

The invention is related to the preparation of I and II [X = O, S, NH and derivatives; Z2, Z3 = independently CH and derivatives, N, wherein none or one of Z2, and Z3 = N; R1 = H, (un)substituted alk(en/yn)yl, (hetero)aryl, etc.; R2 = H, CF3, CN, SH and derivatives, SO2NH2 and derivatives, etc.; R3 = (un)substituted carbocyclyl, heterocyclyl, (hetero)/aryl] and their pharmaceutically acceptable salts which are useful for inhibiting receptor tyrosine kinases and for treating disorders mediated thereby. Methods of using compounds I and II and their stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathol. conditions are disclosed. Thus, pyrazolopyridine III was prepared by a multi-step synthesis via 1-(4-methoxybenzyl)-1H-pyrazolo[3,4-b]pyridin-4-ol intermediate which was obtained from 1-(4-methoxybenzyl)-1H-pyrazol-5-amine and Meldrum’s acid. Certain I and II had IC50’s < 1 μM in a c-Met enzyme assay. The experimental process involved the reaction of 1-(4-Methoxybenzyl)-1H-pyrazolo[3,4-b]pyridin-4-ol(cas: 924909-16-0).Related Products of 924909-16-0

The Article related to heterobicyclic pyrazole preparation tyrosine kinase inhibitor antiproliferative, pyrazolopyridine preparation met kinase inhibitor antitumor hyperproliferative disease, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazoles and other aspects.Related Products of 924909-16-0

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

On January 7, 2016, Chen, Wei; Wang, Longcheng; Yan, Shunqi; Loury, David J.; Jia, Zhaozhong J.; Frye, Leah Lynn; Greenwood, Jeremy Robert; Shelley, Mee Yoo; Atallah, Gordana Babic; Zanaletti, Riccardo; Catalani, Maria Pia; Raveglia, Luca Francesco published a patent.Recommanded Product: 924909-16-0 The title of the patent was Preparation of substituted pyrazolopyridines as inhibitors of Bruton’s tyrosine kinase. And the patent contained the following:

The title compounds I [one of W1 and W2 = C(R9), or N; and the other C(R9); Z = C(R9) or N; L1 = N(R5), O, S or alkyl; T1 = O, N(R5), S, alkylene, or a single bond; Cy1 = substituted aryl or heteroaryl; Cy2 = (un)substituted heterocycloalkyl, aryl, cycloalkyl, or heteroaryl; R1 = H, halo, alkyl, etc; R5 = H, alkyl, heteroalkyl; or when each of L1 and T1 = (independently) N(R5), then the two R5 may join together to form (un)substituted heterocycle; each R9 = (independently) H, halo, CN, etc.] that inhibit Bruton’s tyrosine kinase (Btk), were prepared and formulated. E.g., a multi-step synthesis of 3-hydrazinylpropanenitrile, was described. The Btk IC50 of compounds I was determined in both a cellular kinase assay and in a cellular functional assay of BCR-induced calcium flux (data given). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds I. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. The experimental process involved the reaction of 1-(4-Methoxybenzyl)-1H-pyrazolo[3,4-b]pyridin-4-ol(cas: 924909-16-0).Recommanded Product: 924909-16-0

The Article related to pyrazolopyridine preparation bruton’s tyrosine kinase btk inhibitor antitumor antiinflammatory, lymphoma autoimmune heteroimmune disease treatment pyrazolopyridine preparation btk inhibitor and other aspects.Recommanded Product: 924909-16-0

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

On March 12, 2009, Demeese, Jason; Gaudino, John; Neitzel, Alicia Tarin; Lunghofer, Paul; Jeongbeob, Seo; Hongqi, Tian; Young, Wendy B.; Sutherlin, Daniel P. published a patent.HPLC of Formula: 924909-16-0 The title of the patent was Preparation of pyrazolopyridines as tyrosine kinase inhibitors. And the patent contained the following:

Title compounds[I, II; X = O, S, NR10; W = O, S, SO, SO2; R1 = H, alkyl, alkenyl, alkynyl, CONR10R11, (substituted) carbocyclyl, heterocyclyl, aryl, heteroaryl, etc.; R2 = H, CF3, cyano, NR10R11, (substituted) alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, etc.; R3 = (substituted) carbocyclyl, heterocyclyl, aryl, heteroaryl; R4 = H, F, Cl, Br, CF3, cyano, NR10R11, OR10, etc.; R10, R11 = H, (substituted) alkyl, alkenyl, alkynyl, carbocyclyl, heteroaryl, etc.], were prepared as c-MET kinase inhibitors (no data). Thus, title compound (III) was prepared in 13 steps from 2,2-dimethyl-1,3-dioxane-4,6-dione, 1-(4-methoxybenzyl)-1H-pyrazol-5-amine, 1,2-difluoro-4-nitrobenzene, 1-(4-fluorophenyl)hydrazine hydrochloride, 1,3-dioxane-4,6-dione, and tert-Bu 4-hydroxypiperidine-1-carboxylate. The experimental process involved the reaction of 1-(4-Methoxybenzyl)-1H-pyrazolo[3,4-b]pyridin-4-ol(cas: 924909-16-0).HPLC of Formula: 924909-16-0

The Article related to pyrazolopyridine preparation tyrosine kinase inhibitor, cmet kinase inhibitor piperidinyloxypyrazolopyridine preparation, cancer stroke diabetes hepatomegaly alzheimers treatment phenoxypyrazolopyridine preparation and other aspects.HPLC of Formula: 924909-16-0

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

On June 2, 2011, Demeese, Jason; Gaudino, John; Neitzel, Alicia Tarin; Lunghofer, Paul; Seo, Jeongbeob; Tian, Hongqi; Young, Wendy B.; Sutherlin, Daniel P. published a patent.Formula: C14H13N3O2 The title of the patent was Preparation of pyrazolopyridines as tyrosine kinase inhibitors. And the patent contained the following:

Compounds of Formulas Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting receptor tyrosine kinases and for treating disorders mediated thereby. Methods of using compounds of Formula Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathol. conditions are disclosed. Title compounds[I, II; X = O, S, NR10; W = O, S, SO, SO2; R1 = H, alkyl, alkenyl, alkynyl, CONR10R11, (substituted) carbocyclyl, heterocyclyl, aryl, heteroaryl, etc.; R2 = H, CF3, cyano, NR10R11, (substituted) alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, etc.; R3 = (substituted) carbocyclyl, heterocyclyl, aryl, heteroaryl; R4 = H, F, Cl, Br, CF3, cyano, NR10R11, OR10, etc.; R10, R11 = H, (substituted) alkyl, alkenyl, alkynyl, carbocyclyl, heteroaryl, etc.], were prepared as c-MET kinase inhibitors (no data). Thus, title compound (III) was prepared in 13 steps from 2,2-dimethyl-1,3-dioxane-4,6-dione, 1-(4-methoxybenzyl)-1H-pyrazol-5-amine, 1,2-difluoro-4-nitrobenzene, 1-(4-fluorophenyl)hydrazine hydrochloride, 1,3-dioxane-4,6-dione, and tert-Bu 4-hydroxypiperidine-1-carboxylate. The experimental process involved the reaction of 1-(4-Methoxybenzyl)-1H-pyrazolo[3,4-b]pyridin-4-ol(cas: 924909-16-0).Formula: C14H13N3O2

The Article related to pyrazolopyridine preparation tyrosine kinase inhibitor, cmet kinase inhibitor piperidinyloxypyrazolopyridine preparation, cancer stroke diabetes hepatomegaly alzheimers treatment phenoxypyrazolopyridine preparation and other aspects.Formula: C14H13N3O2

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics